228422-49-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-3-(4-FLUOROPHENYL)-BETA-ALANINOL is used as a key intermediate in the synthesis of aminopyrimidine derivatives, which are known to modulate kinase activity. Kinases are enzymes that play a crucial role in cellular signaling pathways, and their dysregulation is often associated with various diseases, including cancer and inflammatory disorders. By modulating kinase activity, these aminopyrimidine derivatives can potentially be developed into therapeutic agents for the treatment of such diseases.
In the synthesis of these aminopyrimidine derivatives, (S)-3-(4-FLUOROPHENYL)-BETA-ALANINOL serves as a building block, providing the necessary structural elements for the formation of the desired compounds. Its chiral nature ensures that the final products have the correct stereochemistry, which is often critical for biological activity and selectivity.
Furthermore, the 4-fluorophenyl group in (S)-3-(4-FLUOROPHENYL)-BETA-ALANINOL can also contribute to the overall properties of the resulting aminopyrimidine derivatives, such as their lipophilicity, stability, and binding affinity to target kinases. This can be particularly important in the design of drugs with improved pharmacokinetic and pharmacodynamic profiles.

InChI:InChI=1/C9H12FNO/c10-8-3-1-7(2-4-8)9(11)5-6-12/h1-4,9,12H,5-6,11H2/t9-/m0/s1

Upstream product

• 325-89-3 3-amino-3-(4-fluorophenyl)propanoic acid 
• 459-57-4 4-fluorobenzaldehyde 

Relevant academic research and scientific papers

Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols

The invention relates to an improved method for producing chiral or enantiomer-enriched beta amino acids, -aldehydes, -ketones and gamma-amino alcohols, during which an allyl amine of formula (I), in which: R1 represents an alkyl radical, a cycloalkyl rad

Methods and fluorinated compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing amyloid-related disease.

Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists

SAR studies of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists resulted in potent compounds. The best compound from the series had a binding affinity of 2 nM.

IMPROVED METHOD FOR PRODUCING CHIRAL OR ENANTIOMER-ENRICHED BETA-AMINO ACIDS, -ALDEHYDES, -KETONES AND GAMMA-AMINO ALCOHOLS

The invention relates to an improved method for producing chiral or enantiomer-enriched beta amino acids, -aldehydes, -ketones and gamma-amino alcohols, during which an allyl amine of formula (I), in which: R1 represents an alkyl radical, a cycloalkyl rad

PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES

Compounds of formula (I): and their use in the inhibition of Trk activity are described.

Precursors for the production of chiral 1,3-aminoalcohols

The disclosure describes novel precursors for the preparation of chiral 1,3-aminoalcohols. The precursors are chiral 4-hydroxycarboxamides, 4-hydroxyhydroxamic acids, or 4-hydroxyhydrazides produced from chiral gamma-lactones, which in turn are derived from 1,4-diols by stereoselective oxidation. The chiral 4-hydroxycarboxamides, 4-hydroxyhydroxamic acids, or 4-hydroxyhydrazides are converted into chiral 1,3-aminoalcohols by stereospecific rearrangement.